Amyotrophic Lateral Sclerosis: Treating the Disease and Providing Patient-centered Care

Details

This free Neurology CME program features 2 activities and offers 0.50 AMA PRA Category 1 Credits™

Upon successful completion of this activity, participants should be better able to:

• Assess edaravone; its mechanisms of action, similarities, and differences from riluzole; and how to use it in clinical practice to reduce the progression of amyotrophic lateral sclerosis (ALS).
• Assess the use of multidisciplinary approaches and patient-centered decision making in the care of patients with ALS.